Neovascularization inhibitor
AssigneeNippon Shinyaku Co., Ltd.
InventorsFusao Ueda, Fumitaka Katoh
Life of this patent
Estimating the term…
Abstract
The invention relates to a neovascularization inhibitor composition comprising a compound of the following general formula I! or a salt thereof, or a solvate thereof, as an active ingredient, ##STR1## wherein R.sup.1 represents hydrogen, optionally substituted alkyl, aralkyl, arylalkenyl, or aryl; R.sup.2 represents optionally substituted alkyl, aralkyl, arylalkenyl, or aryl; or R.sup.1 and R.sup.2 conjoinedly and taken together with the adjacent N atom, i.e. in the form of NR.sup.1 R.sup.2, represent a 4- through 8-membered cyclic amino group optionally containing nitrogen, oxygen, or sulfur as a ring member in addition to said N atom and optionally being further substituted.
Claims21
A method of effecting neovascular inhibition in humans or animals which comprises the step of administering to said humans or animals a therapeutically effective amount of a compound of the following formula I! or a salt thereof, or a solvate thereof, ##STR5## wherein R.sup.1 represents hydrogen, optionally substituted alkyl, aralkyl, arylalkenyl, or aryl;
- R.sup.2 represents optionally substituted alkyl, aralkyl, arylalkenyl, or aryl;
- or R.sup.1 and R.sup.2 conjoinedly and taken together with the adjacent N atom, i.e. in the form of NR.sup.1 R.sup.2, represent a 4- through 8-membered cyclic amino group optionally containing nitrogen, oxygen, or sulfur as a ring member in addition to said N atom and optionally being further substituted.
A method of treating arteriosclerosis in humans or animals which comprising administering to said humans or animals a therapeutically effective amount of a compound of the following formula (I) or a salt thereof, or a solvate thereof:
- ##STR6## wherein R.sup.1 represents hydrogen, optionally substituted alkyl, aralkyl, arylalkenyl, or aryl;
- R.sup.2 represents optionally substituted alkyl, aralkyl, arylalkenyl, or aryl;
- or R.sup.1 and R.sup.2 conjoinedly and taken together with the adjacent N atom, i.e. in the form of NR.sup.1 R.sup.2, represent a 4- through 8-membered cyclic amino group optionally containing nitrogen, oxygen, or sulfur as a ring member in addition to said N atom and optionally being further substituted.
A method of treating Kaposi's sarcoma in humans or animals which comprising administering to said humans or animals a therapeutically effective amount of the compound of the following formula (I) or a salt thereof, or a solvate thereof ##STR7## wherein R.sup.1 represents hydrogen, optionally substituted alkyl, aralkyl, arylalkenyl, or aryl;
- R.sup.2 represents optionally substituted alkyl, aralkyl, arylalkenyl, or aryl;
- or R.sup.1 and R.sup.2 conjoinedly and taken together with the adjacent N atom, i.e. in the form of NR.sup.1 R.sup.2, represent a 4- through 8-membered cyclic amino group optionally containing nitrogen, oxygen, or sulfur as a ring member in addition to said N atom and optionally being further substituted.
A method of treating diabetic retinopathy in humans or animals which comprising administering to said humans or animals a therapeutically effective amount of a compound of the following formula (I) or a salt thereof, or a solvate thereof ##STR8## wherein R.sup.1 represents hydrogen, optionally substituted alkyl, aralkyl, arylalkenyl, or aryl;
- R.sup.2 represents optionally substituted alkyl, aralkyl, arylalkenyl, or aryl;
- or R.sup.1 and R.sup.2 conjoinedly and taken together with the adjacent N atom, i.e. in the form of NR.sup.1 R.sup.2, represent a 4- through 8-membered cyclic amino group optionally containing nitrogen, oxygen, or sulfur as a ring member in addition to said N atom and optionally being further substituted.
A method of treating rheumatoid arthritis in humans or animals which comprising administering to said humans or animals a therapeutically effective amount of a compound of the following formula (I) or a salt thereof, or a solvate thereof, ##STR9## wherein R.sup.1 represents hydrogen, optionally substituted alkyl, aralkyl, arylalkenyl, or aryl;
- R.sup.2 represents optionally substituted alkyl, aralkyl, arylalkenyl, or aryl;
- or R.sup.1 and R.sup.2 conjoinedly and taken together with the adjacent N atom, i.e. in the form of NR.sup.1 R.sup.2, represent a 4- through 8-membered cyclic amino group optionally containing nitrogen, oxygen, or sulfur as a ring member in addition to said N atom and optionally being further substituted.
Dependencies are inferred from the claim text.